Strides Pharma wipes losses, up 3.4% as JV gets US FDA nod for tapeworm infection drug

Shares of Strides Pharma Science rose as much as 3.4 percent after the company's joint venture received the US FDA's approval for its tapeworm infection treatment drug.

The joint venture -- Strides Vivimed -- received approval from the US Food and Drug Administration (FDA) for its Albendazole  Tablets USP 200 mg.

The stock was down around 3.2 percent on BSE in early trade today.